Corixa (company)
This article needs additional citations for verification. (July 2020) |
Type | biotechnology/pharmaceutical |
---|---|
Founded | 1994 in Seattle, Washington |
Defunct | March 31, 2006 |
Successor | acquired by GlaxoSmithKline |
Headquarters | Seattle , Washington |
Number of locations | 2 |
Parent | GlaxoSmithKline (United States) |
Corixa was a biotechnology/pharmaceutical company based in Seattle, Washington involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer. It was founded in 1994. It operated a laboratory and production facility in Hamilton, Montana.
The name Corixa comes from the true bug (Insecta: Hemiptera: Heteroptera) genus Corixa (family Corixidae, Water boatman), described by Geoffroy, in 1762.
On 12 July 2005[citation needed], the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa.[1] GSK had formerly made use of the Corixa's MPL (Monophosphoryl lipid A, a derivative of the lipid A molecule), an adjuvant in some of their vaccines.
On 31 March 2006, Corixa's doors closed after over 11 years in business.
External links[]
- "Corixa Corporation - powering the immune system". Archived from the original on 2006-03-01.
References[]
- ^ "Glaxo to acquire Corixa for $300 million". Market Watch. April 29, 2005.
Coordinates: 47°36′58″N 122°20′03″W / 47.615976°N 122.334242°W
- Biotechnology companies of the United States
- Defunct companies based in Seattle
- Pharmaceutical companies established in 1994
- Biotechnology companies established in 1994
- Biotechnology companies disestablished in 2006
- 1994 establishments in Washington (state)
- 2006 disestablishments in Washington (state)
- Pharmaceutical companies disestablished in 2006
- GlaxoSmithKline
- Medical company stubs